IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v20y2019i5d10.1007_s10198-019-01040-7.html
   My bibliography  Save this article

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

Author

Listed:
  • Cuc Thi Thu Nguyen

    (Hanoi University of Pharmacy)

  • Fabio Petrelli

    (University of Camerino)

  • Stefania Scuri

    (University of Camerino)

  • Binh Thanh Nguyen

    (Hanoi University of Pharmacy)

  • Iolanda Grappasonni

    (University of Camerino)

Abstract

Objective To review and assess the quality of the available evidence on the cost-effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer (NSCLC). Methods A systematic review was conducted to identify full-text original economic evaluations of erlotinib in the first-line treatment of advanced NSCLC written in English and published from the year 2000 onwards. Study characteristics and results were recorded and compared. The quality of the studies was assessed by the Quality of Health Economic Studies (QHES) questionnaire. Results Eleven out of 130 papers were chosen for this review. Comparative regimens consisted of a best supportive care, reverse strategy, bevacizumab, cisplatin plus pemetrexed, carboplatin plus gemcitabine or gefitinib. The methods most used in these studies were modeling and sensitivity analysis and cost-effectiveness analysis. All of the studies evaluated direct costs and used quality-adjusted life-year (QALY) and life-years gained (LYG) as outcome, with 3% and 3.5% discount rate. The studies assigned ICER that ranged from dominant to I$305,510.31/QALY and from I$31,209.55/LYG to I$66,540.20/LYG. Based on the willingness to pay threshold, seven studies concluded that erlotinib was cost-effective, two studies showed that erlotinib was cost-effective on specific patients with certain conditions, and two studies comparing erlotinib with reverse strategy did not find a difference in cost-effectiveness. The high quality of these studies was confirmed using the QHES tool: the mean score was 75.77 out of 100 (SD 9.38). Conclusion Most of these high-quality studies suggested that erlotinib was cost-effective in the first-line treatment of advanced NSCLC.

Suggested Citation

  • Cuc Thi Thu Nguyen & Fabio Petrelli & Stefania Scuri & Binh Thanh Nguyen & Iolanda Grappasonni, 2019. "A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 763-777, July.
    • Handle: RePEc:spr:eujhec:v:20:y:2019:i:5:d:10.1007_s10198-019-01040-7
    DOI: 10.1007/s10198-019-01040-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-019-01040-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-019-01040-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. World Bank, 2015. "World Development Indicators 2015," World Bank Publications - Books, The World Bank Group, number 21634.
    2. Anne Jäkel & Melanie Plested & Kuntal Dharamshi & Rakhee Modha & Sarah Bridge & Adam Johns, 2013. "A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 27-43, February.
    3. Siying Wang & Liubao Peng & Jianhe Li & Xiaohui Zeng & Lihui Ouyang & Chongqing Tan & Qiong Lu, 2013. "A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-9, March.
    4. Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
    5. Nicky J. Welton & Howard H. Z. Thom, 2015. "Value of Information," Medical Decision Making, , vol. 35(5), pages 564-566, July.
    6. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
    7. Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot, 2012. "Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 30(1), pages 17-34, January.
    8. Pooja Desai & Hitesh Chandwani & Karen Rascati, 2012. "Assessing the Quality of Pharmacoeconomic Studies in India," PharmacoEconomics, Springer, vol. 30(9), pages 749-762, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eun-A Lim & Haeyoung Lee & Eunmi Bae & Jaeok Lim & Young Kee Shin & Sang-Eun Choi, 2016. "Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-14, August.
    2. Szu-Chun Yang & Wu-Wei Lai & Jason C Hsu & Wu-Chou Su & Jung-Der Wang, 2020. "Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-13, April.
    3. Lee, Alice J. & Ames, Daniel R., 2017. "“I can’t pay more” versus “It’s not worth more”: Divergent effects of constraint and disparagement rationales in negotiations," Organizational Behavior and Human Decision Processes, Elsevier, vol. 141(C), pages 16-28.
    4. Hussain, Hadia & Murtaza, Murtaza & Ajmal, Areeb & Ahmed, Afreen & Khan, Muhammad Ovais Khalid, 2020. "A study on the effects of social media advertisement on consumer’s attitude and customer response," MPRA Paper 104675, University Library of Munich, Germany.
    5. A. G. Fatullayev & Nizami A. Gasilov & Şahin Emrah Amrahov, 2019. "Numerical solution of linear inhomogeneous fuzzy delay differential equations," Fuzzy Optimization and Decision Making, Springer, vol. 18(3), pages 315-326, September.
    6. Arun Advani & William Elming & Jonathan Shaw, 2023. "The Dynamic Effects of Tax Audits," The Review of Economics and Statistics, MIT Press, vol. 105(3), pages 545-561, May.
    7. Philippe Aghion & Ufuk Akcigit & Matthieu Lequien & Stefanie Stantcheva, 2017. "Tax simplicity and heterogeneous learning," CEP Discussion Papers dp1516, Centre for Economic Performance, LSE.
    8. Richard Chisik & Nazanin Behzadan & Harun Onder & Apurva Sanghi, 2016. "Aid, Remittances, the Dutch Disease, Refugees, and Kenya," Working Papers 062, Toronto Metropolitan University, Department of Economics.
    9. Al Zayed, Islam Sabry & Elagib, Nadir Ahmed & Ribbe, Lars & Heinrich, Jürgen, 2016. "Satellite-based evapotranspiration over Gezira Irrigation Scheme, Sudan: A comparative study," Agricultural Water Management, Elsevier, vol. 177(C), pages 66-76.
    10. Corno, Lucia & Voena, Alessandra, 2023. "Child marriage as informal insurance: Empirical evidence and policy simulations," Journal of Development Economics, Elsevier, vol. 162(C).
    11. Marie Bjørneby & Annette Alstadsæter & Kjetil Telle, 2018. "Collusive tax evasion by employers and employees. Evidence from a randomized fi eld experiment in Norway," Discussion Papers 891, Statistics Norway, Research Department.
    12. Chuangen Gao & Shuyang Gu & Jiguo Yu & Hai Du & Weili Wu, 2022. "Adaptive seeding for profit maximization in social networks," Journal of Global Optimization, Springer, vol. 82(2), pages 413-432, February.
    13. Koessler, Frederic & Laclau, Marie & Renault, Jérôme & Tomala, Tristan, 2022. "Long information design," Theoretical Economics, Econometric Society, vol. 17(2), May.
    14. Iseghohi Judith Omon, 2021. "Migrant Remittances and Health Outcomes in the West Africa Monetary Zones (WAMZ)," Romanian Economic Journal, Department of International Business and Economics from the Academy of Economic Studies Bucharest, vol. 24(81), pages 15-32, September.
    15. Rentschler, Jun, 2016. "Incidence and impact: The regional variation of poverty effects due to fossil fuel subsidy reform," Energy Policy, Elsevier, vol. 96(C), pages 491-503.
    16. Annette Alstadsæter & Wojciech Kopczuk & Kjetil Telle, 2019. "Social networks and tax avoidance: evidence from a well-defined Norwegian tax shelter," International Tax and Public Finance, Springer;International Institute of Public Finance, vol. 26(6), pages 1291-1328, December.
    17. Sheng, Yu & Xu, Xinpeng, 2019. "The productivity impact of climate change: Evidence from Australia's Millennium drought," Economic Modelling, Elsevier, vol. 76(C), pages 182-191.
    18. Sebastian Kaumanns, 2019. "“Some fuzzy math”: relational information on debt value adjustments by managers and the financial press," Business Research, Springer;German Academic Association for Business Research, vol. 12(2), pages 755-794, December.
    19. Samuel J Gershman, 2015. "A Unifying Probabilistic View of Associative Learning," PLOS Computational Biology, Public Library of Science, vol. 11(11), pages 1-20, November.
    20. Garfield O. Blake, 2015. "Using Increases in Criminal Deportees from the US to Estimate the Effect of Crime on Economic Growth and Development in Latin America and the Caribbean," Laws, MDPI, vol. 4(4), pages 1-18, November.

    More about this item

    Keywords

    Cost-effectiveness; Overview; Report’s quality; QHES;
    All these keywords.

    JEL classification:

    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:20:y:2019:i:5:d:10.1007_s10198-019-01040-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.